In Ontario, Canada, trastuzumab plus chemotherapy has been funded for the treatment of adjuvant HER2+ breast cancer by the New Drug Funding Program (NDFP) since 1 August 2005 [3]. This evidence concerns the gene ERBB2 and breast cancer.